Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Glioblastoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1

Interventions

Rituximab 130Cyclophosphamide 41Bendamustine Hydrochloride 39venetoclax 25fludarabine 25obinutuzumab 24Lenalidomide 23ibrutinib 22Gemcitabine 22Vincristine 20Prednisone 20tositumomab I-131 19Doxorubicin 19plerixafor 14Dexamethasone 14Granulocyte Colony-Stimulating Factor 12pirtobrutinib 11Brentuximab Vedotin 11glofitamab 10tocilizumab 9pembrolizumab 9ibritumomab tiuxetan 9Etoposide 9Azacitidine 9polatuzumab vedotin 8parsaclisib 8copanlisib 8acalabrutinib 8Drug Therapy 8ublituximab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, Non-Hodgkin × TPI-287 × Clear all
NCT00113724 2009-06-04

Study of TPI 287 in Patients With Advanced Malignancies

Cortice Biosciences, Inc.

Phase 1 Completed
48 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

NCT00256191 2007-10-15

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

Cortice Biosciences, Inc.

Phase 1 Completed
45 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡